Emerging trends in the novel drug delivery approaches for the treatment of lung cancer

Publication date: Available online 18 June 2019Source: Chemico-Biological InteractionsAuthor(s): Parvarish Sharma, Meenu Mehta, Daljeet Singh Dhanjal, Simran Kaur, Gaurav Gupta, Harjeet Singh, Lakshmi Thangavelu, S. Rajesh Kumar, Murtaza Tambuwala, Hamid A. Bakshi, Dinesh Kumar Chellappan, Kamal Dua, Saurabh SatijaAbstractCancer is one of the major diseases that cause a high number of deaths globally. Of the major types of cancers, lung cancer is known to be the most chronic form of cancer in the world. The conventional management of lung cancer includes different medical interventions like chemotherapy, surgical removal, and radiation therapy. However, this type of approach lacks specificity and also harms the adjacent normal cells. Lately, nanotechnology has emerged as a promising intervention in the management and treatment of lung cancers. Nanotechnology has revolutionized the existing modalities and focuses primarily on reducing toxicity and improving the bioavailability of anticancer drugs to the target tumor cells. Nanocarrier systems are being currently used extensively to exploit and to overcome the obstructions induced by cancers in the lungs. The nano-carrier-loaded therapeutic drug delivery methods have shown promising potential in treating lung cancer as its target is to control the growth of tumor cells. In this review, various modes of nano drug delivery options like liposomes, dendrimers, quantum dots, carbon nanotubes and metallic nanoparticles have been disc...
Source: Chemico Biological Interactions - Category: Biochemistry Source Type: research

Related Links:

Metastatic lung cancer has long represented a therapeutic challenge, with treatment primarily consisting of systemic chemotherapy, with limited long-term survival. Patients with limited sites ( ≤ 5) of metastatic disease, known as oligometastatic disease, may derive improved outcomes from aggressive local therapy. Stereotactic ablative radiation therapy (SABR) represent a promising new method of conformal aggressive treatment to oligometastic disease. Herein we report analysis of a prosp ective multi-center phase II trial assess the safety and feasibility of SABR for oligometastatic non-small-cell lung cancer.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Publish Only Source Type: research
ConclusionIn patients not suitable of concurrent radio-chemotherapy, exclusive or sequential hypofractionated schedule using 60  Gy in 20 fractions was well tolerated and presented promising results. Complete local response was a predictor of better outcomes, and any efforts will be made to perform prospective clinical trials to further evaluate hypofractionated regimens with increased lesional BED.
Source: La Radiologia Medica - Category: Radiology Source Type: research
ConclusionsOur study revealed the clinical characteristics and prognoses of patients who became ineligible for the PACIFIC trial after CRT. Physicians should be careful while prescribing CRT for patients with characteristics such as old age, male gender, and radiation therapy with V20  ≥ 35%.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
AbstractPurposeTo evaluate alterations in pulmonary function indices after helical tomotherapy and explore potential associations with biologically corrected dosimetric parameters.Patients and methodsIn 64  patients with inoperable locally advanced non-small cell lung cancer, pulmonary function tests before and within 6 months after radiotherapy were evaluated retrospectively. In the case of concurrent chemotherapy a total dose of 67.2 Gy was delivered, otherwise 70.5 Gy was provided. In 44 pa tients, late pulmonary function changes (≥6 months after radiotherapy) could also be assessed.Resul...
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
This study was designed to compare survival outcomes for non-surgically managed T1-T2N0M0 small cell lung cancer (SCLC) patients who received either stereotactic body radiation therapy (SBRT) or conventionally fractionated radiotherapy (CFRT) using the National Cancer Database (NCDB).MethodsThe NCDB was queried between 2004 and 2015 for patients with T1-T2N0M0 SCLC. Patients must have been treated with curative intent SBRT or CFRT (delivered daily or twice daily, 45 –70 Gy) with or without chemotherapy. The primary outcome was overall survival (OS). A subset analysis of patients receiving chemotherapy was also p...
Source: Journal of Radiation Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: SBRT was well-tolerated in the treatment of stage I SCLC with excellent LC achieved. Patients with T1N0 stage IA SCLC were noted to have improved PFS and OS following SBRT as compared with T2N0 Stage IB SCLC. Adjuvant chemotherapy was found to result in improved OS for stage I SCLC patients over SBRT alone. PMID: 31232723 [PubMed - in process]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Am J Clin Oncol Source Type: research
Abstract Cancer is one of the major diseases that cause a high number of deaths globally. Of the major types of cancers, lung cancer is known to be the most chronic form of cancer in the world. The conventional management of lung cancer includes different medical interventions like chemotherapy, surgical removal, and radiation therapy. However, this type of approach lacks specificity and also harms the adjacent normal cells. Lately, nanotechnology has emerged as a promising intervention in the management and treatment of lung cancers. Nanotechnology has revolutionized the existing modalities and focuses primarily ...
Source: Chemico-Biological Interactions - Category: Molecular Biology Authors: Tags: Chem Biol Interact Source Type: research
There has been no recent randomized evidence justifying postoperative radiation therapy (PORT) in patients with non-small cell lung cancer who have undergone complete resection; it is not recommended for routine use, even in patients with mediastinal involvement (pN2).1,2 Adjuvant treatments such as chemotherapy and PORT should be discussed at a multidisciplinary board with complete surgical and pathologic reports, checking whether the nodal exploration was appropriate, the location and number of mediastinal nodes and hilar/intrapulmonary nodes that were resected, and whether resection was complete.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
Conclusions: Percutaneous CT fluoroscopy-guided permanent seed brachytherapy is a safe, efficacious, and cost effective primary and salvage treatment for lung cancer. CT-fluoroscopy resources are readily available in the community and are an effective alternative to stereotactic body radiation therapy (SBRT), intensity-modulated radiation therapy (IMRT)/proton beam, radiofrequency ablation (RFA), and cryoablation (CA). Percutaneous CT fluoroscopy-guided permanent seed brachytherapy has an equivalent or better local control rate, a lower resource cost, and a far lower integral radiation dose than other therapies. We believe...
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
Conclusions: The average increase in the GC SUVmean in patients with left lower lung lesions was significantly greater than that in patients with left upper or right lung lesions. Therefore, in our study, the most radiation-induced cardiotoxicity was seen in patients with left lower lung lesions. These findings may be useful to consider in RT treatment planning, and also suggest the need for closer cardiac monitoring post-RT in this group of patients.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Image-Guided Therapy Posters Source Type: research
More News: Biochemistry | Cancer | Cancer & Oncology | Chemistry | Chemotherapy | Lung Cancer | Nanotechnology | Radiation Therapy | Toxicology